SCHEMBL21617268

SCHEMBL21617268

c1ccc(COc2ccc(Nc3cccc(OCCCC4CCCCC4)c3)c(C3CC3)c2)nc1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ SIRT2 Q8IXJ6 1/20 0.40
▸ RHOA P61586 2/20 0.40
▸ MET P08581 2/20 0.38
▸ MEN1 O00255 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ IGF1R P08069 1/20 0.35
▸ TLR4 O00206 1/20 0.35
▸ TLR2 O60603 1/20 0.35
▸ CNR2 P34972 2/20 0.35
▸ HRH3 Q9Y5N1 2/20 0.35
▸ MCHR1 Q99705 1/20 0.35
▸ MAPK14 Q16539 1/20 0.35
▸ ALOX5AP P20292 1/20 0.35
▸ FEN1 P39748 1/20 0.35
▸ SLC6A4 P31645 1/20 0.35
▸ DGAT1 O75907 1/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31504397 1.00 SIRT2 (0.40) SIRT2RHOAMETMEN1HPGD
SCHEMBL31504395 0.91 CHRNA1 (0.36) RHOAMETMEN1HPGDKMT2A
SCHEMBL21617271 0.91 CHRNA1 (0.36) RHOAMETMEN1HPGDKMT2A
SCHEMBL21617294 0.86 EGFR (0.43) SIRT2RHOAMETMEN1HPGD
SCHEMBL31504390 0.86 EGFR (0.43) SIRT2RHOAMETMEN1HPGD
SCHEMBL21623405 0.85 CNR2 (0.39) SIRT2RHOAMETMEN1KMT2A
SCHEMBL31504346 0.85 CNR2 (0.39) SIRT2RHOAMETMEN1KMT2A
SCHEMBL21623436 0.84 RHOA (0.36) SIRT2RHOAMETIGF1RHRH3
SCHEMBL21623433 0.84 KMT2A (0.48) SIRT2RHOAMEN1HPGDKMT2A
SCHEMBL21623513 0.83 EGFR (0.43) RHOAMEN1KMT2AIGF1RTLR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3820850-B1 PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2026-04-01 — — EP disclosed
US-12421206-B2 Aryl-n-aryl derivatives for treating a RNA virus infection ABIVAX (FR) 2025-09-23 — — US disclosed
EP-3820850-A1 PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2021-05-19 — — EP disclosed
US-20210122732-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2021-04-29 — — US disclosed
US-20210122732-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2021-04-29 — — US disclosed
WO-2020011816-A1 PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2020-01-16 — — WO disclosed
WO-2020011816-A1 PHENYL/PYRIDYL-N-PHENYL/PYRIDYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION ABIVAX (FR) 2020-01-16 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12421206-B2 Aryl-n-aryl derivatives for treating a RNA virus infection NSUN3, CBR3, C1R SIRT2 2763/4885RHOA 4460/4885MET 410/4885
US-20210122732-A1 ARYL-N-ARYL DERIVATIVES FOR TREATING A RNA VIRUS INFECTION NSUN3, CBR3, C1R SIRT2 2763/4885RHOA 4460/4885MET 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback